NL-OMON23963尚未招募不适用
A double blind, placebo controlled Phase 2 dose ranging study of the effects ofARA 290 on corneal nerve fiber density and neuropathic symptoms of patientswith sarcoidosis.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 64
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •The subjects will have to present the following criteria:
- •Established diagnosis of sarcoidosis with any of the following two criteria:
排除标准
- •The subjects should not present any of the following criteria:
- • Clinically relevant abnormal history of physical and mental health other than
- •conditions related to sarcoidosis, as determined by medical history taking (as
- •judged by the investigator)
研究者
相似试验
进行中（未招募）
不适用
study the safety and effects of different doses of ARA 290 administered subcutaneously on the corneal nerve fiber density and symptoms of neuropathic pain in sarcoidosis patients.small fiber neuropathyEUCTR2013-003016-45-NLAraim Pharmaceuticals64
已完成
2 期
A double blind, placebo controlled Phase 2 dose ranging study of the effects of ARA 290 on corneal nerve fiber density and neuropathic symptoms of subjects with sarcoidosischronic pain in sarcoidosis patientsSarcoid neuropathy1002766510034606NL-OMON38804ARAIM Pharmaceuticals32
招募中
1 期
An early-stage clinical study of a potential new medicine for patients with Netherton Syndromeetherton's SyndromeMedDRA version: 20.0Level: PTClassification code: 10062909Term: Netherton's syndrome Class: 100000004850CTIS2022-502853-32-00Daiichi Sankyo Inc.12
尚未招募
1 期
Phase 1b/2 Study of DS-7011a in Patients with Systemic Lupus Erythematosus (SLE)Systemic Lupus Erythematosus (SLE)JPRN-jRCT2031230588Inoguchi Akihiro24
尚未招募
1 期
To evaluate the Safety and Immunogenicity of a single dose â??Dengue Tetravalent Vaccine in healthy subjects.CTRI/2017/02/007923Panacea Biotec Ltd200